Business Context and Reporting Period
Spero Therapeutics, Inc. (SPRO), a Delaware corporation, filed this Form 8-K on February 28, 2025, reporting an event that occurred on February 25, 2025. The company is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding a listing deficiency and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq. The Company's common stock closing bid price remained below the $1.00 per share minimum requirement for 30 consecutive trading days prior to February 25, 2025, violating Nasdaq Listing Rule 5450(a)(1). The stock continues to trade on the Nasdaq Global Select Market pending compliance.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has until August 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Secondary Compliance Option: If the initial deadline is missed, the Company may be eligible for an additional 180-day period, contingent upon transferring its listing to the Nasdaq Capital Market and meeting initial listing standards (excluding the bid price requirement).
- Remedial Actions: Management may consider a reverse stock split to cure the deficiency during the additional compliance period, subject to Nasdaq approval.
- Delisting Risk: Failure to cure the deficiency within the allowed periods could result in delisting. While the Company has the right to appeal a delisting determination, there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of SPRO to assess proximity to the $1.00 threshold.
- Monitor upcoming announcements regarding the potential implementation of a reverse stock split.
- Review the Company's cash position in other filings to determine if it has sufficient liquidity to fund operations while addressing the listing deficiency.
- Track the status of the compliance period leading up to the August 25, 2025, deadline.